Press Benjamin H, Lokeshwar Soum D, Webb Lindsey, Khajir Ghazal, Smani Shayan, Olawoyin Olamide, Gardezi Mursal, Rahman Syed N, Leapman Michael S, Sprenkle Preston C
Department of Urology, Yale School of Medicine, New Haven, CT 06510, USA.
Explor Target Antitumor Ther. 2024;5(6):1168-1176. doi: 10.37349/etat.2024.00269. Epub 2024 Sep 13.
Prostate biopsy can be prone to complications and thus should be avoided when unnecessary. Although the combination of magnetic resonance imaging (MRI), the prostate health index (PHI), and PHI density (PHID) has been shown to improve detection of clinically significant prostate cancer (csPCa), there is limited information available assessing its clinical utility. We sought to determine whether using PHID could enhance the detection of PCa on MRI ultrasound fusion-targeted biopsy (MRF-TB) compared to other biomarker cutoffs.
Between June 2015 and December 2020, 302 men obtained PHI testing before MRF-TB at a single institution. We used descriptive statistics, multivariable logistic regression, and receiver operating characteristic curves to determine the predictive accuracy of PHID and PHI to detect ≥ Gleason grade group (GGG) 2 PCa and identify cutoff values.
Any cancer grade was identified in 75.5% of patients and ≥ GGG2 PCa was identified in 45% of patients. The median PHID was 1.05 [interquartile range (IQR) 0.59-1.64]. A PHID cutoff of 0.91 had a higher discriminatory ability to predict ≥ GGG2 PCa compared to PHI > 27, PHI > 36, and prostate specific-antigen (PSA) density > 0.15 (AUC: 0.707 vs. 0.549 vs. 0.620 vs. 0.601), particularly in men with Prostate Imaging Reporting and Data System (PI-RADS) 1-2 lesions on MRI (AUC: 0.817 vs. 0.563 vs. 0.621 vs. 0.678). At this cutoff, 35.0% of all the original biopsies could be safely avoided (PHID < 0.91 and no ≥ GGG2 PCa) and csPCa would be missed in 9.67% of patients who would have been biopsied. In patients with PI-RADS 1-2 lesions using a PHID cutoff of 0.91, 56.8% of biopsies could be safely avoided while missing 0 csPCa.
These findings suggest that a PHID cutoff of 0.91 improves the selection of patients with elevated prostate-specific antigen who are referred for prostate biopsy, and potentially in patients with PI-RADS 1-2 lesions.
前列腺活检容易出现并发症,因此在不必要时应避免进行。虽然磁共振成像(MRI)、前列腺健康指数(PHI)和PHI密度(PHID)的联合应用已被证明可提高临床显著性前列腺癌(csPCa)的检测率,但评估其临床效用的可用信息有限。我们试图确定与其他生物标志物临界值相比,使用PHID是否能在MRI超声融合靶向活检(MRF-TB)中提高前列腺癌(PCa)的检测率。
2015年6月至2020年12月期间,302名男性在单一机构进行MRF-TB之前接受了PHI检测。我们使用描述性统计、多变量逻辑回归和受试者操作特征曲线来确定PHID和PHI检测≥Gleason分级组(GGG)2级PCa的预测准确性,并确定临界值。
75.5%的患者被诊断出患有任何癌症分级,45%的患者被诊断出患有≥GGG2级PCa。PHID的中位数为1.05[四分位间距(IQR)0.59 - 1.64]。与PHI>27、PHI>36和前列腺特异性抗原(PSA)密度>0.15相比,PHID临界值为0.91在预测≥GGG2级PCa方面具有更高的鉴别能力(曲线下面积[AUC]:0.707对0.549对0.620对0.601),特别是在MRI上前列腺影像报告和数据系统(PI-RADS)1 - 2级病变的男性中(AUC:0.817对0.563对0.621对0.678)。在此临界值下,所有原始活检中有35.0%可以安全避免(PHID<0.91且无≥GGG2级PCa),而在本应接受活检的患者中,9.67%的患者会漏诊csPCa。在使用PHID临界值0.91的PI-RADS 1 - 2级病变患者中,56.8%的活检可以安全避免,同时不会漏诊任何csPCa。
这些发现表明,PHID临界值为0.91可改善对因前列腺特异性抗原升高而被转诊进行前列腺活检患者的选择,对于PI-RADS 1 - 2级病变的患者可能也是如此。